Next 10 |
Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for ...
2024-03-28 15:00:00 ET More on the markets Where This Market Is Going (Technical Analysis) SPY: 2 Opposing Forces Wall Street Lunch: Fed Not Spooked By Recent Inflation Overbought conditions flash across all market caps: Bespoke Investment Group Energ...
2024-03-24 08:01:00 ET Westport Fuel Systems ( WPRT ) is set to report its Q4 earnings on Monday after the closing bell. The stock, which has dropped about 24% over a 12-month period, has received a Buy rating from Wall Street analysts, while Seeking Alpha's Quant Rating system has ...
Findings presented at SGO 2024 show 87% of respondents afraid of making long-term plans due to the possibility of a shorter life expectancy 84% say dealing with treatment side effects has negatively impacted their emotional well-being, and 94% worry about LGSOC returning despite treatment...
2024-03-14 17:16:51 ET More on Verastem Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy Verastem gets FDA fast track status for lung cancer drug combo Seek...
Initiated confirmatory Phase 3 RAMP 301 trial evaluating avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer; on track to submit rolling NDA for accelerated approval in H1 2024; preparations underway for potential commercial launch in 2025 Granted FDA Fast...
Late-breaking oral presentation of a subgroup analysis in RAMP 201 Part A heavily pretreated patients receiving avutometinib and defactinib and their best response compared to most recent prior therapy Plenary oral presentation of preclinical efficacy of the combination of avutometinib an...
2024-03-11 05:50:46 ET More on related stocks: Oracle Q3 Earnings Preview: Cloud Computing Business In Focus Blink Charging: EV Tailwinds Offer A Path To Profitability In 2025 Ulta Beauty: We Are Not Adding To Our Position Before The Earnings Release (Rating Downgrad...
2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
2024-03-06 05:48:01 ET Read the full article on Seeking Alpha For further details see: Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy
News, Short Squeeze, Breakout and More Instantly...
Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for ...
Findings presented at SGO 2024 show 87% of respondents afraid of making long-term plans due to the possibility of a shorter life expectancy 84% say dealing with treatment side effects has negatively impacted their emotional well-being, and 94% worry about LGSOC returning despite treatment...
Initiated confirmatory Phase 3 RAMP 301 trial evaluating avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer; on track to submit rolling NDA for accelerated approval in H1 2024; preparations underway for potential commercial launch in 2025 Granted FDA Fast...